SG11201804885TA - Monomaleimide-functionalized platinum compounds for cancer therapy - Google Patents
Monomaleimide-functionalized platinum compounds for cancer therapyInfo
- Publication number
- SG11201804885TA SG11201804885TA SG11201804885TA SG11201804885TA SG11201804885TA SG 11201804885T A SG11201804885T A SG 11201804885TA SG 11201804885T A SG11201804885T A SG 11201804885TA SG 11201804885T A SG11201804885T A SG 11201804885TA SG 11201804885T A SG11201804885T A SG 11201804885TA
- Authority
- SG
- Singapore
- Prior art keywords
- wien
- international
- monomaleimide
- pct
- platinum compounds
- Prior art date
Links
- 229940045985 antineoplastic platinum compound Drugs 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 150000003058 platinum compounds Chemical class 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198739 | 2015-12-09 | ||
| PCT/EP2016/080453 WO2017097986A1 (en) | 2015-12-09 | 2016-12-09 | Monomaleimide-functionalized platinum compounds for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804885TA true SG11201804885TA (en) | 2018-07-30 |
Family
ID=54849106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804885TA SG11201804885TA (en) | 2015-12-09 | 2016-12-09 | Monomaleimide-functionalized platinum compounds for cancer therapy |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10723748B2 (enExample) |
| EP (1) | EP3386997B1 (enExample) |
| JP (1) | JP6867652B2 (enExample) |
| CN (1) | CN108368143B (enExample) |
| AU (1) | AU2016367306B2 (enExample) |
| CA (1) | CA3004630A1 (enExample) |
| CY (1) | CY1124529T1 (enExample) |
| DK (1) | DK3386997T3 (enExample) |
| ES (1) | ES2898704T3 (enExample) |
| HR (1) | HRP20211466T1 (enExample) |
| HU (1) | HUE056897T2 (enExample) |
| IL (1) | IL259864B (enExample) |
| LT (1) | LT3386997T (enExample) |
| MX (1) | MX377528B (enExample) |
| PL (1) | PL3386997T3 (enExample) |
| PT (1) | PT3386997T (enExample) |
| RS (1) | RS62412B1 (enExample) |
| SG (1) | SG11201804885TA (enExample) |
| SI (1) | SI3386997T1 (enExample) |
| SM (1) | SMT202100709T1 (enExample) |
| WO (1) | WO2017097986A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101915452B1 (ko) * | 2014-06-23 | 2018-11-06 | 플라콘 테라퓨틱스 인코포레이티드 | 백금 화합물, 조성물 및 이의 용도 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109171001A (zh) * | 2018-09-14 | 2019-01-11 | 上海烟草集团有限责任公司 | 草酸钠在降低卷烟烟气中TSNAs释放量中的应用 |
| JP2023508996A (ja) * | 2019-12-31 | 2023-03-06 | キネート バイオファーマ インク． | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 |
| CN114163479B (zh) * | 2020-09-11 | 2025-05-16 | 上海海聚生物科技有限公司 | 一类治疗癌症用的铂类化合物及其制备方法 |
| US20230339997A1 (en) * | 2020-09-11 | 2023-10-26 | Shanghai Haiju Biological Technology Co., Ltd. | Class of platinum compounds for treating cancer, and method for preparation thereof |
| CN114539320A (zh) * | 2020-11-25 | 2022-05-27 | 北京大学 | 辐射激活的四价铂配合物及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CH605550A5 (enExample) | 1972-06-08 | 1978-09-29 | Research Corp | |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| CS269719B1 (en) | 1986-12-29 | 1990-05-14 | Kiss Frantisek | Platinum cytostatic |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| WO1999016421A1 (en) | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| AUPQ641100A0 (en) | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| DK1280520T4 (en) | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
| ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
| DE10314780A1 (de) | 2003-03-19 | 2004-09-30 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden |
| HRP20050902A2 (en) | 2003-03-31 | 2005-12-31 | Pliva-Lachema A.S. | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof |
| CZ2004945A3 (cs) | 2004-09-08 | 2006-01-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| CZ296459B6 (cs) | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| US20060205810A1 (en) | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| CZ300120B6 (cs) | 2006-06-20 | 2009-02-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| CZ300424B6 (cs) | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
| CZ300590B6 (cs) | 2006-06-20 | 2009-06-24 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| KR102057356B1 (ko) * | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법 |
| CN105722847A (zh) * | 2013-10-08 | 2016-06-29 | 阿特莱斯遗传学有限公司 | 标记化合物和它们在测定中的用途 |
| EP3089745A4 (en) | 2013-12-31 | 2017-05-17 | Placon Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of cancers |
| KR101915452B1 (ko) * | 2014-06-23 | 2018-11-06 | 플라콘 테라퓨틱스 인코포레이티드 | 백금 화합물, 조성물 및 이의 용도 |
| JP6876631B2 (ja) | 2015-06-23 | 2021-05-26 | プラコン セラピューティクス インコーポレイテッドＰｌａｃｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 白金化合物、組成物及びその使用 |
| US20180186823A1 (en) | 2015-06-23 | 2018-07-05 | Placon Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| WO2017004123A1 (en) | 2015-06-29 | 2017-01-05 | Case Western Reserve University | Anticancer drug-containing plant virus particles |
| AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| TW202434291A (zh) | 2016-07-08 | 2024-09-01 | 美商建南德克公司 | 人類副睪蛋白4 (he4)用於評定癌症治療反應性之用途 |
| WO2018026742A1 (en) | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
| CN108164512B (zh) | 2017-12-27 | 2021-05-25 | 沈阳药科大学 | 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用 |
| CN108187063B (zh) | 2018-01-09 | 2020-09-08 | 沈阳药科大学 | 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药 |
-
2016
- 2016-12-09 AU AU2016367306A patent/AU2016367306B2/en not_active Ceased
- 2016-12-09 CA CA3004630A patent/CA3004630A1/en active Pending
- 2016-12-09 HR HRP20211466TT patent/HRP20211466T1/hr unknown
- 2016-12-09 SG SG11201804885TA patent/SG11201804885TA/en unknown
- 2016-12-09 SM SM20210709T patent/SMT202100709T1/it unknown
- 2016-12-09 JP JP2018529981A patent/JP6867652B2/ja active Active
- 2016-12-09 CN CN201680072428.4A patent/CN108368143B/zh not_active Expired - Fee Related
- 2016-12-09 PL PL16822917T patent/PL3386997T3/pl unknown
- 2016-12-09 DK DK16822917.7T patent/DK3386997T3/da active
- 2016-12-09 IL IL259864A patent/IL259864B/en unknown
- 2016-12-09 PT PT16822917T patent/PT3386997T/pt unknown
- 2016-12-09 EP EP16822917.7A patent/EP3386997B1/en active Active
- 2016-12-09 HU HUE16822917A patent/HUE056897T2/hu unknown
- 2016-12-09 US US16/060,559 patent/US10723748B2/en active Active
- 2016-12-09 LT LTEPPCT/EP2016/080453T patent/LT3386997T/lt unknown
- 2016-12-09 SI SI201631342T patent/SI3386997T1/sl unknown
- 2016-12-09 RS RS20211187A patent/RS62412B1/sr unknown
- 2016-12-09 WO PCT/EP2016/080453 patent/WO2017097986A1/en not_active Ceased
- 2016-12-09 ES ES16822917T patent/ES2898704T3/es active Active
- 2016-12-09 MX MX2018006953A patent/MX377528B/es active IP Right Grant
-
2020
- 2020-06-17 US US16/904,528 patent/US11572379B2/en active Active
-
2021
- 2021-09-27 CY CY20211100840T patent/CY1124529T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3386997T3 (pl) | 2021-12-13 |
| RS62412B1 (sr) | 2021-10-29 |
| CN108368143B (zh) | 2022-02-01 |
| HRP20211466T1 (hr) | 2021-12-24 |
| US10723748B2 (en) | 2020-07-28 |
| JP6867652B2 (ja) | 2021-05-12 |
| US11572379B2 (en) | 2023-02-07 |
| AU2016367306B2 (en) | 2021-04-22 |
| SMT202100709T1 (it) | 2022-01-10 |
| CA3004630A1 (en) | 2017-06-15 |
| IL259864B (en) | 2022-07-01 |
| DK3386997T3 (da) | 2021-09-20 |
| HUE056897T2 (hu) | 2022-03-28 |
| CN108368143A (zh) | 2018-08-03 |
| SI3386997T1 (sl) | 2021-11-30 |
| IL259864A (en) | 2018-07-31 |
| LT3386997T (lt) | 2021-12-10 |
| CY1124529T1 (el) | 2022-07-22 |
| US20210002313A1 (en) | 2021-01-07 |
| ES2898704T3 (es) | 2022-03-08 |
| PT3386997T (pt) | 2021-11-04 |
| EP3386997A1 (en) | 2018-10-17 |
| MX2018006953A (es) | 2019-05-16 |
| JP2018538292A (ja) | 2018-12-27 |
| AU2016367306A1 (en) | 2018-06-14 |
| WO2017097986A1 (en) | 2017-06-15 |
| MX377528B (es) | 2025-03-10 |
| US20180354979A1 (en) | 2018-12-13 |
| EP3386997B1 (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201804890TA (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |